EFFICACY OF RECURRENT TREATMENT WITH RITUXIMAB IN PATIENT WITH SEVERE REFRACTORY SYSTEMIC TYPE OF JUVENILE RHEUMATOID ARTHRITIS

Voprosy Sovremennoj Pediatrii. 2009;8(6):85-91

 

Journal Homepage

Journal Title: Voprosy Sovremennoj Pediatrii

ISSN: 1682-5527 (Print); 1682-5535 (Online)

Publisher: "Paediatrician" Publishers LLC

Society/Institution: The Union of Pediatricians of Russia

LCC Subject Category: Medicine: Pediatrics

Country of publisher: Russian Federation

Language of fulltext: Russian, English

Full-text formats available: PDF

 

AUTHORS

S.I. Valieva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.I. Alexeeva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
E.Yu. Gudkova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
T.M. Bzarova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
K.B. Isaeva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
R.V. Denisova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
A.O. Lisitsin (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
T.V. Sleptsova (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)
A.A. Grigor'eva (Scientific Center of Children’s Health, Russian Academy of Medical Sciences, Moscow)

EDITORIAL INFORMATION

Blind peer review

Editorial Board

Instructions for authors

Time From Submission to Publication: 8 weeks

 

Abstract | Full Text

<em>The article presents a case report of severe clinical course of systemic type of juvenile rheumatoid arthritis refractory to the immunosuppressive treatment. The disease was characterized with such extra-articular symptoms as fever, lymphadenopathia, hepatosplenomegaly, polyserositis. Generalized joints lesion and high laboratory signs of disease’s activity presented. Significant hormone-dependence and hormone-resistance on the ground of corticosteroids developed. Inclusion of rituximab to the scheme of treatment stopped systemic symptoms of a disease, inflammatory lesions in joints, and normalized laboratory rates of activity. Beneficial effect of treatment allowed lowering of peroral corticosteroids’ dose. Obtained results testify to high effectiveness of rituximab. This medication can be the drug of choice in a treatment of children with systemic type of juvenile rheumatoid arthritis, refractory to immunosuppressive therapy and corticosteroids.</em><br /><strong><em>Key words: children, systemic type of juvenile rheumatoid arthritis, rituximab.</em></strong><br /><span style="text-decoration: underline;"><em>(<em><em><em>Voprosy sovremennoi pediatrii — </em></em></em>Current Pediatrics. 2009;8(6):<em>85-91</em>)</em></span>